ONEMEDNET CORPORATION (ONMD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 4.73M USD | Liabilities, Current |
| Cash and equivalents | 358.00K USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 664.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.73M | $358.00K | (m) | $664.00K | (m) | (m) |
| 2026-03-31 | (m) | $5.36M | $233.00K | (m) | $697.00K | (m) | (m) |
| 2025-12-31 | (m) | $4.83M | $585.00K | (m) | $495.00K | (m) | (m) |
| 2025-09-30 | (m) | $5.00M | $149.00K | (m) | $582.00K | (m) | (m) |
| 2025-06-30 | (m) | $6.16M | $122.00K | (m) | $254.00K | (m) | (m) |
| 2025-03-31 | (m) | $18.15M | $144.00K | (m) | $247.00K | (m) | (m) |
| 2024-12-31 | (m) | $19.23M | $172.00K | (m) | $213.00K | (m) | (m) |
| 2024-09-30 | (m) | $18.63M | $1.93M | (m) | $63.00K | (m) | (m) |
| 2024-06-30 | (m) | $20.05M | $407.00K | (m) | $75.00K | (m) | (m) |
| 2024-03-31 | (m) | $14.66M | $174.00K | (m) | $253.00K | (m) | (m) |
| 2023-12-31 | (m) | $12.83M | $47.01K | (m) | $151.64K | (m) | (m) |
| 2023-09-30 | (m) | $14.28M | $611.82K | (m) | $86.39K | (m) | (m) |
| 2023-06-30 | (m) | $2.09M | $3.44K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.34M | $10.11K | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.98M | $30.87K | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.45M | $234.92K | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.17M | $7.48K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $566.41K | $159.13K | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $289.98K | $453.15K | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $16.13K | $533.71K | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $51.81K | $802.11K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $25.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |